When did Supernus Pharmaceuticals report Q4 2024 earnings?

Supernus Pharmaceuticals (SUPN) reported Q4 2024 earnings on February 25, 2025 after market close.

What were Supernus Pharmaceuticals's Q4 2024 revenue and EPS?

Supernus Pharmaceuticals reported revenue of $174.2M and eps of $0.75 for Q4 2024.

Did Supernus Pharmaceuticals beat estimates in Q4 2024?

Revenue beat the consensus estimate of $155.3M by $18.9M. EPS beat the consensus estimate of $0.46 by $0.29.

Where can I find Supernus Pharmaceuticals's Q4 2024 SEC filings?

You can read the 10-K periodic report (0001356576-25-000017) directly on SEC EDGAR. The filing index links above go to sec.gov.

Supernus Pharmaceuticals SUPN Q4 2024 Annual earnings

Reported February 25, 2025 · After market close

Revenue$174.2MBeat by $18.9M

EPS$0.75Beat by $0.29

Revenue estimate$155.3M

EPS estimate$0.46

Next report

Aug 4, 2026 (In 6 days)

Revenue estimate$205.3M

EPS estimate$0.42

Financials

Q4 2024

Income statement

See full

Revenue$174.2M+6.0%

Gross profit$148.1M+2.3%

Operating income$21.4M+2,249%

Net income$15.3M+1,205%

EPS (diluted)$0.27+1,250%

Balance sheet

See full

Cash & equivalents$69.3M-7.6%

Total debt$34.3M-17.5%

Total equity$1.0B+12.4%

Total assets$1.4B+7.1%

Cash flow

See full

Operating cash flow$44.4M-1.2%

CapEx$213.0K—

Free cash flow$44.2M-1.8%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$2B+26.3%

Enterprise value$1.96B+26.7%

P/E27×-1,175×

P/S3×+0.4×

Profitability

See full

Gross margin88.2%+2.0pp

Operating margin12.3%+11.6pp

Net margin11.2%+10.9pp

FCF margin25.9%—

Returns & leverage

See full

Return on equity7.5%+7.4pp

Debt / equity0×0.0×

Current ratio2.3×+0.6×

Segments

By product

See full

Qelbree$74.4M+60.5%

GOCOVRI$36.9M+15.4%

APOKYN$20.1M+7.2%

Trokendi XR$14.8M-24.5%

Oxtellar XR$13.2M-57.5%

By segment

See full

Reportable Segment$174.2M+14.7%

Versus estimates

Revenue

Q1 2026$207.7MBeat by $14.8M Q4 2025$211.6MBeat by $16.4M Q3 2025$192.1MMiss by $2.6M Q2 2025$165.5MMiss by $2.8M Q1 2025$149.8MBeat by $1.9M

Q4 2024$174.2MBeat by $18.9M

Diluted EPS

Q1 2026$0.59Beat by $0.31 Q4 2025$0.92Beat by $0.64 Q3 2025$1.01Beat by $0.19 Q2 2025$0.91Beat by $0.44 Q1 2025$0.42Beat by $0.04

Q4 2024$0.75Beat by $0.29

Ask the moment Supernus Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Supernus Pharmaceuticals report Q4 2024 earnings?: Supernus Pharmaceuticals (SUPN) reported Q4 2024 earnings on February 25, 2025 after market close.
What were Supernus Pharmaceuticals's Q4 2024 revenue and EPS?: Supernus Pharmaceuticals reported revenue of $174.2M and eps of $0.75 for Q4 2024.
Did Supernus Pharmaceuticals beat estimates in Q4 2024?: Revenue beat the consensus estimate of $155.3M by $18.9M. EPS beat the consensus estimate of $0.46 by $0.29.
Where can I find Supernus Pharmaceuticals's Q4 2024 SEC filings?: You can read the 10-K periodic report (0001356576-25-000017) directly on SEC EDGAR. The filing index links above go to sec.gov.